Should intravesical Bacillus Calmette-Guerin be employed in transplant recipients with bladder carcinoma?

被引：13
|
作者：
Sun, H. -Y. [1 ,2 ]
Singh, N. [1 ,3 ]
机构：
[1] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA
[2] Natl Taiwan Univ, Coll Med, Dept Internal Med, Natl Taiwan Univ Hosp, Taipei, Taiwan
[3] Univ Pittsburgh, Div Infect Dis, Pittsburgh, PA USA
来源：
TRANSPLANT INFECTIOUS DISEASE | 2010年 / 12卷 / 04期
关键词：
transplant; bladder carcinoma; pro-inflammatory; responses; Bacillus Calmette-Guerin; BCG; PHASE-III TRIAL; KIDNEY-TRANSPLANTATION; BCG IMMUNOTHERAPY; MYCOBACTERIUM-BOVIS; IN-SITU; IMMUNOSUPPRESSIVE DRUGS; EUROPEAN ORGANIZATION; IMMUNE-RESPONSES; CANCER INCIDENCE; MESSENGER-RNA;
D O I：
10.1111/j.1399-3062.2010.00506.x
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Bacillus Calmette-Guerin (BCG) exerts its antitumor activity through induction of pro-inflammatory cytokines, while immunosuppressive agents prevent organ rejection by suppressing pro-inflammatory and promoting anti-inflammatory responses. Thus, in the setting of transplant populations, the use of intravesical BCG for bladder cancer has the possibility of either promoting allograft rejection or being rendered ineffective by the action of immunosuppressive agents that block pro-inflammatory responses. We discuss the potential immunologic interactions between BCG and immunosuppression, and review relevant outcomes in renal transplant recipients with bladder cancer receiving intravesical BCG.
引用
收藏
页码：358 / 362
页数：5
相关论文
共 50 条
  • [41] POLYARTHRITIS IN 4 PATIENTS TREATED WITH INTRAVESICAL BACILLUS OF CALMETTE-GUERIN (BCG) FOR BLADDER-CARCINOMA
    BELMATOUG, N
    LEVYDJEBBOUR, S
    APPELBOOM, T
    DEGENNES, C
    PELTIER, AP
    MEYER, O
    KAHN, MF
    CARBON, C
    [J]. REVUE DU RHUMATISME, 1993, 60 (02): : 162 - 166
  • [42] Prostatorectal fistula following intravesical bacillus Calmette-Guerin immunotherapy for carcinoma in situ of the urinary bladder
    Enatsu, Noritoshi
    Ota, Tomonori
    Ochi, Atsuhiko
    [J]. INTERNATIONAL JOURNAL OF UROLOGY, 2010, 17 (09) : 822 - 823
  • [43] MONITORING INTRAVESICAL BACILLUS CALMETTE-GUERIN TREATMENT OF BLADDER-CARCINOMA WITH FLOW-CYTOMETRY
    STAIANOCOICO, L
    HUFFMAN, J
    WOLF, R
    PINSKY, CM
    HERR, HW
    WHITMORE, WE
    OETTGEN, HF
    DARZYNKIEWICZ, Z
    MELAMED, MR
    [J]. JOURNAL OF UROLOGY, 1985, 133 (05): : 786 - 788
  • [44] SQUAMOUS-CELL CARCINOMA OF BLADDER AFTER SUCCESSFUL INTRAVESICAL THERAPY WITH BACILLUS CALMETTE-GUERIN
    BRENNER, DW
    YORE, LM
    SCHELLHAMMER, PF
    [J]. UROLOGY, 1989, 34 (02) : 93 - 95
  • [45] PULMONARY GRANULOMATA - A COMPLICATION OF INTRAVESICAL ADMINISTRATION OF BACILLUS CALMETTE-GUERIN FOR SUPERFICIAL BLADDER-CARCINOMA
    SMITH, RL
    ALEXANDER, RF
    ARANDA, CP
    [J]. CANCER, 1993, 71 (05) : 1846 - 1847
  • [46] EXPERIENCE WITH BACILLUS CALMETTE-GUERIN IN PATIENTS WITH SUPERFICIAL BLADDER-TUMORS - VALUE OF MONOCYTE ACTIVATION IN INTRAVESICAL BACILLUS CALMETTE-GUERIN THERAPY
    NISSENKORN, I
    LAVIE, G
    KEISARI, Y
    LEIB, Z
    VILCOVSKY, E
    SERVADIO, C
    SHACHTER, H
    [J]. EUROPEAN UROLOGY, 1987, 13 (04) : 246 - 250
  • [47] Acute eosinophilic pneumonia associated with intravesical bacillus Calmette-Guerin therapy of carcinoma in situ of the bladder
    Orikasa, K
    Namima, T
    Ota, S
    Miura, M
    Hama, H
    Kimura, N
    Ohnuma, T
    [J]. INTERNATIONAL JOURNAL OF UROLOGY, 2003, 10 (11) : 622 - 624
  • [48] Treatment of carcinoma in situ with intravesical bacillus Calmette-Guerin without maintenance
    Griffiths, TRL
    Charlton, M
    Neal, DE
    Powell, PH
    [J]. JOURNAL OF UROLOGY, 2002, 167 (06): : 2408 - 2412
  • [49] Bacillus Calmette-Guerin and bladder cancer
    Razack, Azad H. A.
    [J]. ASIAN JOURNAL OF SURGERY, 2007, 30 (04) : 302 - 309
  • [50] OUTCOME IN CARCINOMA INSITU OF BLADDER TREATED WITH INTRAVESICAL BACILLE CALMETTE-GUERIN
    HARLAND, SJ
    CHARIG, CR
    HIGHMAN, W
    PARKINSON, MC
    RIDDLE, PR
    [J]. BRITISH JOURNAL OF UROLOGY, 1992, 70 (03): : 271 - 275
12345